

A dark blue horizontal banner with a white circle on the left side containing the text "PRESS RELEASE" in white capital letters.

PRESS RELEASE

## Sosei Heptares to present at 38<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco

Tokyo, Japan and London, UK, 26 December 2019 – Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 15, 2020.

The presentation will begin at 10:30 a.m. Pacific Time in the Elizabethan A room at the Westin St. Francis Hotel. The presentation will be webcast live in English and can be accessed [here](#) or via the investor section of the Company’s Home Page, [www.soseiheptares.com](http://www.soseiheptares.com).

– Ends –

### About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR<sup>®</sup> technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.

We have established partnerships with some of the world’s leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR<sup>®</sup> are Trade Marks of Sosei Group companies.

For more information, please visit <https://www.soseiheptares.com/>

LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

### Enquiries:

#### Sosei Heptares

Shinichiro Nishishita – VP Investor Relations

+81 (0)3 5210 3399 | [IR@SoseiHeptares.com](mailto:IR@SoseiHeptares.com)

Candelle Chong – VP Corporate Strategy and Communications

+44 (0)1223 949 392 | [Comms@SoseiHeptares.com](mailto:Comms@SoseiHeptares.com)

---

 **PRESS RELEASE****Citigate Dewe Rogerson**

Yas Fukuda – Japanese Media

+81 (3) 4360 9241 | [Yas.Fukuda@citigatedewerogerson.com](mailto:Yas.Fukuda@citigatedewerogerson.com)

Mark Swallow, David Dible – International Media

+44 (0)20 7638 9571 | [SoseiHeptares@citigatedewerogerson.com](mailto:SoseiHeptares@citigatedewerogerson.com)**Forward-looking statements**

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.